ANI Pharmaceuticals, Inc. ANIP
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a specialty pharmaceutical company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Cortrophin Gel | acute gouty arthritis flares, MS, RA, nephrotic syndrome | protein/peptide | Approved |
| ILUVIEN | DME and chronic NIU-PS | small molecule | Approved |
| YUTIQ | NIU-PS | small molecule | Approved |
Recent results and decisions
- Sep 28, 2026approval EMCITATE (tiratricol) approved by FDA for peripheral thyrotoxicosis in patients with MCT8 deficiency.
EMCITATE® (tiratricol) is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.